3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms by Site
3
Neoplasms
3
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Digestive System Neoplasms
2
Digestive System Diseases
2
Colorectal Neoplasms
2
Thoracic Neoplasms
1
Stomach Neoplasms
1
Respiratory Tract Neoplasms
1
Rectal Diseases
1
Previously Treated Metastatic Colorectal Cancer
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Colonic Diseases
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Non-Small-Cell Lung
1
Bronchial Neoplasms
1
Adenocarcinoma
1
Interventions
Carboplatin
67
Cisplatin
57
Paclitaxel
42
Radiotherapy
35
Pemetrexed
34
Gemcitabine
31
Docetaxel
31
Etoposide
25
pembrolizumab
21
Vinorelbine
20
Erlotinib Hydrochloride
13
Magnetic Resonance Spectroscopy
12
Gefitinib
11
Specimen Handling
10
Radiosurgery
10
Drug Therapy
10
Bevacizumab
10
durvalumab
9
Nivolumab
9
Vinblastine
6
Topotecan
6
Surgical Procedures, Operative
6
Cyclophosphamide
6
atezolizumab
5
Standard of Care
5
Platinum
5
Immunoglobulin G
5
Ifosfamide
5
Disulfides
5
Dexamethasone
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lung Neoplasms
×
napabucasin
×
Clear all
NCT02826161
2023-11-15
CanStem43L
Sumitomo Pharma America, Inc.
Phase 3
Terminated
4 enrolled
6 charts